Recursion Pharmaceuticals Inc (RXRX) Stock Price Today
Key Stats
- $1.73BMarket Cap
- 14,763,320Volume
- HealthSector
- $6.7952W High
- $2.8452W Low
- 22 DaysTypical Hold Time
- $1.25BEnterprise Value
- -Div Yield
- 32% Sell | 68% BuyTrading Activity
Track Recursion Pharmaceuticals Inc (RXRX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Recursion Pharmaceuticals Inc has traded between a low of $2.84 and a high of $6.79, highlighting its annual price range. Buy and sell Recursion Pharmaceuticals Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Most Recent News
Stocks surge on patent wins, financing deals, and merger announcements.
Several stocks saw sharp gains driven by key company developments. bioAffinity Technologies surged 63.55% after securing a Hong Kong patent for its lung cancer diagnostic technology, boosting its Asian market position. Antelope Enterprise Holdings ro...
Citi launches Mastercard's Smart Subscriptions tool in UAE for better digital subscription management
Citi has introduced Mastercard's Smart Subscriptions tool in the UAE, allowing cardholders to manage all digital subscriptions via the Citi banking app. This is Citi's first global deployment of the tool and Mastercard's first in the Middle East. The...
Crusoe raises $3.9B, valuing AI data center firm at $30.9B with new modular AI factory plans.
Crusoe, a data center developer focused on AI infrastructure, raised $3.9 billion in a Series F funding round, boosting its valuation to $30.9 billion. The funding will support existing large-scale projects like the Abilene, Texas site used by OpenAI...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.